0000899243-21-021576.txt : 20210602
0000899243-21-021576.hdr.sgml : 20210602
20210602173511
ACCESSION NUMBER: 0000899243-21-021576
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210528
FILED AS OF DATE: 20210602
DATE AS OF CHANGE: 20210602
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: West Linda
CENTRAL INDEX KEY: 0001805257
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39114
FILM NUMBER: 21990378
MAIL ADDRESS:
STREET 1: C/O GALERA THERAPEUTICS, INC.
STREET 2: 2 W LIBERTY BLVD., #110
CITY: MALVERN
STATE: PA
ZIP: 19355
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Galera Therapeutics, Inc.
CENTRAL INDEX KEY: 0001563577
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 461454898
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 WEST LIBERTY BLVD #100
CITY: MALVERN
STATE: PA
ZIP: 19355
BUSINESS PHONE: 610-725-1500
MAIL ADDRESS:
STREET 1: 2 WEST LIBERTY BLVD #100
CITY: MALVERN
STATE: PA
ZIP: 19355
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-05-28
0
0001563577
Galera Therapeutics, Inc.
GRTX
0001805257
West Linda
C/O GALERA THERAPEUTICS, INC.,
2 W LIBERTY BLVD #100
MALVERN
PA
19355
1
0
0
0
Common Stock
2021-05-28
4
P
0
10000
8.641
A
10000
D
Common Stock
2021-06-01
4
P
0
10000
8.6381
A
20000
D
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.59 to $8.6759, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.59 to $8.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
/s/ Chris Degnan, Attorney-in-Fact for Linda West
2021-06-02